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Randomized controlled trial to study plaque inhibition in calcium sodium 
phosphosilicate dentifrices  
 
Abstract 
Objectives: To evaluate the effect of three calcium sodium phosphosilicate (CSPS)/sodium 
monofluorophosphate containing dentifrices, compared to positive and negative controls on 
plaque re-growth in a non-brushing model, after 4 days of twice daily use, as determined by 
plaque area and Turesky plaque index (TPI). 
Methods: This was an exploratory, single-centre, examiner-blind, randomised, controlled, 
five treatment period, crossover, plaque re-growth study, with supervised use of study 
products. Twenty-three healthy adult volunteers were randomized to receive experimental 5% 
CSPS dentifrice; two marketed 5% CSPS dentifrices; active comparator mouthrinse and 
negative control dentifrice. At the start of each treatment period, zero plaque was established 
by dental prophylaxis and study products were dispensed as either dentifrice slurries or 
mouthrinse, twice daily for the next 4 days. No other forms of oral hygiene were permitted. 
After 96 hours, supra-gingival plaque was determined by plaque area (direct entry, 
planimetric method) and TPI. Changes from zero plaque were analysed. 
Results: For both measures, plaque re-growth at 96 hours was significantly lower following 
treatment with active comparator mouthrinse and significantly higher following treatment 
with the experimental 5% CSPS dentifrice, compared to all other treatments. There were no 
statistically significant differences between the three other treatments, except between the 
marketed 5% CSPS dentifrices, for overall plaque area. 
Conclusions: The comparator mouthwash was significantly more effective at preventing 
plaque accumulation than the dentifrice slurries. The three marketed dentifrices contained 
sodium lauryl sulphate and were more effective at reducing plaque re-growth than the 
experimental dentifrice formulated with a tegobetaine/adinol surfactant system.  
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Clinical relevance 
The CSPS containing dentifrices tested in this study showed no significant chemical-
therapeutic anti-plaque benefits compared to a negative control dentifrice.  However, sodium 
lauryl sulphate-containing dentifrices controlled plaque more effectively than a 
tegobetaine/adinol-containing CSPS dentifrice suggesting that the impact of surfactant 
selection on anti-plaque activity of formulations warrants further investigation. 
 
NHS REC Reference: 12/SW/0294 
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Introduction 
Dental plaque is a soft, sticky deposit of bacteria that collects on the teeth and along the 
gingival margin. Bacterial by-products from dental plaque can affect the health of the gingiva 
by causing inflammation of the gingival tissue (gingivitis). Whilst gingivitis is reversible, if 
untreated it can progress to periodontitis in susceptible individuals, which can result in bone 
loss and ultimately tooth loss (1). Gingivitis and periodontal disease can develop when dental 
plaque accumulates above levels compatible with oral health(2-4), management of gingivitis 
therefore being both a primary prevention strategy for periodontitis and a secondary 
prevention strategy for recurrent periodontitis. The maintenance of gingival health and the 
prevention of gingivitis are predominantly determined by the control of dental plaque(5). The 
mechanical action of tooth brushing alone is often insufficient for most individuals to achieve 
adequate plaque control(6-8); in a recent systematic review it was demonstrated that an average 
of only 42% of plaque is removed in a single brushing(9). As tooth-brushing with dentifrice is 
the most common oral hygiene regime, dentifrices are an obvious choice for the delivery of 
anti-plaque agents and many have been developed to chemically inhibit plaque deposition or 
augment its removal(3). 
 
Active ingredients (such as metal salts, triclosan, cetylpyridinium chloride and chlorhexidine) 
have been incorporated into dentifrices for many years with a view to delivering plaque 
control and oral health benefits(10). While some efficacy has been demonstrated for metal salts, 
a meta-analysis of stannous fluoride demonstrated significant heterogeneity in the findings of 
clinical studies(11)and most studies have shown zinc salts to be effective only when used in 
combination with other agents such as triclosan or chlorhexidine(10). Triclosan has been 
shown to be effective against plaque and gingivitis in two systematic reviews(12-13); however, 
a second systematic review with different inclusion/exclusion criteria failed to demonstrate 
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the same efficacy(11). Furthermore, while triclosan is known to be safe for use in toothpaste 
formulations(14), its use in a wide range of healthcare products have resulted in an 
accumulation of it and its breakdown products in the environment(15). Triclosan is not readily 
decontaminated, and concerns about its long term impact on health and bacterial resistance 
are now being raised(15). To date, chlorhexidine is the most effective active ingredient tested. 
It has been shown to reduce plaque and improve gingival health(16); however, the side effects 
of tooth-staining and altered taste sensation have resulted in the continued quest for other 
ingredients with similar efficacy. 
 
Calcium sodium phosphosilicate (CSPS) (Novamin®; GSK Consumer Healthcare, Brentford, 
UK) is a particulate bioactive material that upon exposure to the aqueous oral environment 
undergoes degradation at the tooth surface, releasing calcium and phosphate ions. This 
reaction is accompanied by a localized rise in pH and results in the formation of a 
hydroxycarbonate apatite-like material(17-19). Studies have shown that particles of CSPS and 
associated silicas within the dentifrice formulation can bind to the dentine surface and within 
the tubules to physically occlude the dentinal tubules in vitro (17,18,20) and in situ(21), giving 
rise to its use as an occlusion agent in desensitizing dentifrices(22). 
 
In addition to its de-sensitizing effects, CSPS has been reported to act as an anti-bacterial 
agent in vitro(23)and, in two clinical studies, to reduce supra-gingival plaque and gingival 
bleeding compared to a placebo dentifrice(24-25). It is postulated that the high rate of ionic 
exchange when bioglasses such as CSPS come into contact with water, the release of large 
quantities of calcium and the localized increases in pH described above, may affect the dental 
plaque and be responsible for these effects(24,26). However, evidence for this is not conclusive 
and further studies to confirm the mode of action and clinical efficacy of CSPS as an anti-
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plaque, anti-gingivitis agent are needed. 
 
A number of plaque indices have been developed to assess the control of supra-gingival 
dental plaque. These can be objective (such as plaque weight) or subjective (such as plaque 
area). Subjective measures require a degree of examiner judgement during data collection(27) . 
The validity and credibility of subjective indices are increased by using more than one index 
to score plaque or by repeating the same subjective index, then assessing the variability of 
repeated measurements(27). 
 
The Turesky modification of the Quigley Hein(28) plaque index (TPI(29)) is a subjective index 
commonly used to assess disclosed plaque. It focuses initially on plaque in contact with the 
gingival margin and gives an ordinal plaque score. By contrast, the assessment of plaque area 
by planimetric means, developed by Addy et al(30) as an adaptation of the Shaw and 
Murray(31)  stain index, is based upon the subjective drawing of the outline of the area of 
disclosed plaque covering the entire scorable surface on a standard tooth chart. Planimetric 
data have been shown to be accurate(32)  and provide an additional level of detail regarding 
plaque levels and distribution, but determining plaque areas from tooth charts on which they 
have been hand drawn is time consuming. 
 
The objective of this study was to evaluate the effect of three 5.0% w/w CSPS/sodium-
monofluorophosphate (SMFP) containing dentifrices, an active comparator mouthwash and a 
negative control dentifrice (with no CSPS) on plaque re-growth in a non-brushing model after 
four days of twice daily use, as measured by plaque area(30) and the TPI. The efficacy data 
generated by the study was used to evaluate and compare results from a new computer-based, 
direct data entry, planimetric methodology for recording and calculating plaque area, with the 
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data derived using the TPI.  
 
Materials and methods 
Study design and methodology 
This study was an exploratory, single centre, examiner blind, randomized, controlled, five 
way crossover in vivo study to investigate the effect of CSPS-containing dentifrices on plaque 
re-growth over four days twice-daily treatment in the absence of tooth brushing. Ethical 
approval for the study was awarded by a UK research ethics committee (NHS Research 
Ethics Committee Reference 12/SW/0294) and the study was conducted to Good Clinical 
Practice guidelines(33). Volunteer recruitment, screening, treatment and clinical assessments 
were carried out at the study site, a UK Dental School. Potential subjects who had expressed 
an interest in the study were invited to screening and allocated a unique screening number 
assigned in ascending numerical order as they gave written informed consent to take part in 
the study. Eligible subjects were aged 18 years or over, and in the investigator’s opinion, 
based on medical history, in good general health.  Volunteers who were pregnant or breast 
feeding, had known allergies or intolerances to study materials, or who were on (or had been 
on) antibiotic or antimicrobial treatment within 14 days of the first treatment visit were 
excluded. Volunteers with diabetes mellitus (Type 1 or 2) or other diseases that could impact 
study outcomes were also excluded. Following an oral examination, participants were 
included if they had at least 20 natural, uncrowned teeth with at least 40 facial/buccal and 
lingual/palatal surfaces gradable for plaque area and TPI. If caries, severe gingivitis or 
periodontal disease was detected participants were excluded. Similarly subjects with 
orthodontics bands or oral lesions that could impact the study outcome were not included. 
Any volunteer with a dental condition requiring immediate treatment or that could worsen as 
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a result of suspending normal oral hygiene procedures during the five treatment periods was 
also excluded. 
 
Volunteers who satisfied the inclusion and exclusion criteria were randomized to the order in 
which they would receive each of the five treatments according to the randomization 
schedule provided by the sponsor. Randomization numbers were assigned by study staff at 
the study site in ascending numerical order as subjects were determined to be fully eligible to 
participate in the study. Following randomization subjects were given sub- and supra-gingival 
prophylaxis with flossing, followed by disclosure and removal of any residual plaque, to 
ensure all stain, calculus and plaque had been removed from the teeth. A second clinician 
confirmed that there was no visible plaque on the participants’ teeth. All subjects were given 
a standard fluoride (washout) dentifrice (UK Colgate Cavity Protection; Colgate-Palmolive 
Ltd, Guildford, UK; 1000 ppm fluoride) and toothbrush to use twice daily for a minimum of 
2 days prior to the start of each treatment period. In addition to using the washout dentifrice, 
participants were asked to adhere to a number of lifestyle restrictions for the duration of the 
trial including refraining from professional tooth cleaning or elective dental procedures, the 
use of dental products (other than those provided), chewing gum and interproximal cleaning 
devices, and tongue brushing. Study subjects were required to abstain from normal oral 
hygiene (i.e. twice daily tooth-brushing with washout toothpaste) for the duration of each 4-
day treatment period.  
 
There were five treatment periods, each of which took place over five consecutive days (Days 
0–4) and followed the same schedule (two visits on Days 0–3 and one on Day 4), with a 
minimum of 2 days between treatment periods. Each subject evaluated one study treatment 
per treatment period, the order of testing being determined by the randomization schedule.  
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On the first visit of a treatment period (Day 0), subjects were given a full oral soft tissue 
(OST) examination and supra-gingival prophylaxis with flossing; zero visible plaque (plaque 
area = 0, TPI = 0) was confirmed by a second clinician. Following this, subjects were given 
the first slurry (1.5 g toothpaste in 10 ml of water) or rinse of their allocated treatment. 
Treatment was administered twice a day on days 0–3 with a minimum of 5 hours between 
treatments. Subjects were required to abstain from eating and drinking for at least 30 minutes 
after each treatment rinse. 
 
On Day 4, subjects visited the study site  (96 ± 2 hours from the time of first treatment on 
Day 0), having refrained from eating, drinking or smoking for at least 4 hours prior to the 
visit (volunteers were permitted to drink water up to 1 hour before plaque assessments). 
Subjects were given a full OST examination and supra-gingival plaque re-growth was 
assessed using plaque area and the TPI. Compliance with all study restrictions was checked at 
each visit to the study site. 
 
Study treatment and mode of application 
Study treatments and treatment preparation/administration are described in Table 1.  
 
Clinical measurements of plaque re-growth 
Supra-gingival plaque accumulation was evaluated (following disclosure using Gum Red 
Cote® disclosing solution; Sunstar Americas, Inc, Chicago, IL) after 4 days treatment using 
the plaque area index described by Addy et al(30) and the six-site modification of the TPI(29) . 
For both measures, only natural teeth in each 7-7 dental arch, where 50% of the tooth surface 
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was gradable (i.e. where restorative materials covered less than 50% of the tooth surface), 
were scored. 
 
TPI was assessed for distal, body and mesial sites on each of the facial/buccal and 
lingual/palatal surfaces of each scorable tooth, according to the scoring system shown in 
Table 2. Plaque area index was determined by drawing the area of disclosed plaque present 
on the facial/buccal and lingual/palatal surfaces of each scorable tooth onto a standard tooth 
chart (Figure 1) (30-31) . Previously, plaque area outlines have been drawn on paper tooth charts 
which are then assessed using a pen driven digitizer to determine the area of plaque coverage. 
By contrast, in the present study an application (Cplaque app, Clinical Trials Unit, 
Periodontology, University of Bristol, UK) that allowed the examiner to draw the plaque area 
outline directly onto a tablet screen was used. Once the image was captured, it was locked as 
original source data with no possibility of further modification. The area of tooth surface 
covered by plaque was calculated automatically and expressed as a percentage of scorable 
area.  
 
Examiner repeatability 
Repeatability data were generated during the study for both computer-based planimetric 
plaque area and TPI from repeat examinations of selected subjects on Day 4. There was a 
minimum of 10 minutes between repeat assessments and, where possible, another subject was 
assessed between the repeat assessments. 
 
Statistical analysis 
As this was an exploratory study no formal sample size calculation was possible. However, 
differences that might be able to be detected together with the probability of finding that 
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these differences were statistically significant at the end of the study were calculated based on 
the data of He et al(34) regarding the distribution of differences in TPI between treatments. 
 
With a reasonable (conservative) assumption on the covariance structure of the repeated 
measures ( = 0.3), an idea of detectable differences in this study was estimated using these 
published data (SE [differences] = 0.04). It was calculated that 20 subjects would provide 
moderate power (80%) of detecting a difference in TPI between two treatments of 0.17 with a 
two sided 5% paired t-test. This does not include any correction for multiplicity. Based on 
this, a sufficient number of subjects were screened to ensure that up to 25 were randomized 
and 20 completed the study.  
 
For data analysis, the changes from zero-plaque following prophylaxis at baseline in 96 hour 
plaque area (mean percentage [%] area of the tooth surface covered by plaque, all surfaces 
and facial/buccal surfaces only) and TPI were analysed using analysis of variance (ANOVA). 
The mixed models had treatment and period as fixed effects. Participant was included as a 
random variable. Two-sided treatment comparison tests were performed at the 5% 
significance level. Treatment differences are presented with 95% confidence intervals. The 
assumptions of normality and homogeneity of variance were investigated and were not 
violated. 
 
Repeatability was assessed using the intra-class correlation coefficient for the plaque area and 
the kappa statistic for the TPI. Data analysis was conducted using SPSS.  
 
Results 
Demographics and tolerance of treatments 
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Screening began on the 17th Jan 2013 and the clinical phase of the study completed on the 
26th April 3013. Twenty three subjects were randomized (19 female and 4 male); all received 
treatment and formed the Safety and Intention to Treat (ITT) populations. Nineteen were 
White (82.6%) and four (17.4%) Asian (native of Asia or of Asian descent), none were 
Hispanic or Latino, with an average age of 38.6 years (range 21–63 years). Twenty one 
subjects completed the entire study; the remaining two participants completed either three or 
four of the five treatment periods.  
 
A total of three subjects reported three treatment-emergent adverse events (TEAEs), none 
were considered to be treatment related or serious and all resolved. Of these, two (dental 
discomfort and nasopharyngitis) were mild and one (influenza) was severe. The single oral 
TEAE (dental discomfort) was reported for the experimental 5% CSPS treatment. There were 
no OST abnormalities or incidents. 
 
Efficacy results 
The efficacy results are based on the ITT population. There were no protocol deviations 
assessed as affecting efficacy and therefore a Per Protocol (PP) analysis was not performed.  
 
Ninety-six hour plaque re-growth, as assessed by mean percentage plaque area, was 
significantly higher following 4 days treatment with the experimental 5% CSPS dentifrice 
with tegobetaine/adinol compared to all other treatments, and significantly lower following 4 
days treatment with the active comparator mouthwash compared to all other treatments 
(Table 3 and Fig. 2A). The results were the same irrespective of whether mean percentage 
plaque area was calculated for all surfaces or just for the facial/buccal surfaces. There were 
no significant differences in plaque re-growth at 96 hours between the two marketed 5% 
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CSPS containing dentifrices and the negative control. There was a very small, but statistically 
significant, difference between the two marketed 5% CSPS dentifrices, favouring marketed 
5% CSPS dentifrice [2], when all surfaces were included in the plaque area calculation 
(2.82%, p=0.0386). 
 
The findings of analysis of the TPI data (Table 3 and Fig. 2B) were similar to those for 
plaque area, with 96 hour plaque re-growth being significantly higher following treatment 
with the experimental 5% CSPS dentifrice containing tegobetaine/adinol, and significantly 
lower following treatment with the active comparator mouthwash compared to all other 
treatments. There were no statistically significant differences between the two marketed 5% 
CSPS containing dentifrices and the negative control. 
 
Examiner repeatability results 
Eleven subjects had repeat assessments of plaque area and TPI and contributed to the 
repeatability analyses. For plaque area the intra-class correlation was 0.974 (95% CI 0.97 to 
0.98), calculated for all surfaces, and 0.969 (95% CI 0.96 to 0.98), calculated for the 
facial/buccal surfaces. For TPI the weighted kappa statistic was 0.94 (95% CI 0.93 to 0.95). 
These levels of agreement are considered excellent. 
 
Discussion 
The accumulation of plaque was first shown to play a causal role in the development of 
gingivitis in the original plaque re-growth study performed by Löe et al(35). Plaque may be 
removed by mechanical means; however, it has been shown that most uninstructed 
individuals brush ineffectively and as a result only modest amounts of plaque are removed(36). 
To improve the plaque control delivered during tooth-brushing, dentifrices are frequently 
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formulated with chemical ingredients that target the plaque bacteria(37) , with new formations 
continually being developed. 
 
A small number of previous studies have reported that CSPS has antimicrobial properties in 
vitro(23) and can reduce plaque and improve gingival health, as compared to a control 
dentifrice, in vivo(24-25). In the present study three dentifrice formulations containing 5% 
CSPS were tested for efficacy against plaque, as compared to an active comparator 
mouthwash (Listerine® Cool Mint Antibacterial Mouthwash) and a negative control dentifrice 
(Crest Decay Prevention). In this non-brushing model, the mouthwash treatment proved the 
most effective against plaque re-growth and was statistically significantly better than all 
dentifrices tested. The mouthwash included in this study (Listerine® Cool Mint Antibacterial 
Mouthwash) was chosen as a comparator as its efficacy has been previously demonstrated in 
a number of clinical studies, including recently a 4 day plaque re-growth study(38)  and a 28 
week clinical study(39). Its efficacy has been further supported by a recent meta-analysis(40) . 
The efficacy reported in this study was therefore expected.  
 
In the present study, no significant differences in plaque control were observed between any 
of the 5% w/w CSPS dentifrices and the negative control dentifrice. This finding does not 
support the anti-plaque activity reported for 5% CSPS dentifrices in two previously published 
clinical studies where the toothpaste was applied by toothbrushing(24-25). The experimental 
5% w/w CSPS dentifrice was the least plaque inhibitory of all the products tested. 
 
The three CSPS-containing dentifrices differed in abrasivity; however, the main difference of 
relevance to a non-brushing study was considered to be the presence of tegobetaine/adinol as 
surfactant in the experimental formulation, compared to SLS in the marketed 5% CSPS 
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dentifrices. SLS was also present in the negative control dentifrice. SLS is an anionic 
surfactant primarily included in dentifrice formulations to enhance foaming and cleaning. In a 
previous in vitro study, dentifrice supernatants containing SLS were shown to detach bacteria 
from the surface of the salivary pellicle(41) and, in vivo, SLS-containing mouthwashes have 
been shown to decrease salivary bacterial counts for up to 7 hours(42). It is possible, therefore, 
that SLS contributed a plaque inhibitory effect to both the marketed 5% w/w CSPS 
dentifrices and the negative control dentifrice in the present study. 
 
The clinical evaluation of new methods and ingredients for plaque control typically begins 
with short-term screening studies(30) , which may vary in length from a matter of hours to 
days. Such studies provide an effective in vivo screen to assess the potential of novel 
technologies prior to the more extensive studies required for validation purposes(43) . The 
methodology employed in this study was considered appropriate to examine the potential 
chemo-therapeutic effect of CSPS delivered from a fully formulated dentifrice. The crossover 
design of the study minimised inter-subject variation. 
 
The assessment of plaque area by planimetric means was developed by Addy et al(30) as an 
adaptation of the Shaw & Murray(31) stain index. Planimetry has been shown to have a high 
discriminating power(44)  and to be recorded accurately with minimal variability between 
examiners(32) . In the present study a modification was made to the planimetry technique with 
the introduction of a tablet application that enabled the examiner to draw directly onto the 
tablet and then have the plaque area calculated. Previously, areas have been recorded by the 
examiner in the clinic on paper toothcharts, followed by calculation of plaque area using a 
pen-driven digitizer at a later date(45) , a time consuming process, the new method being able 
to calculate the plaque area immediately after recording at chairside. As planimetry is 
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subjective in nature, and a new method of electronically capturing the data was employed, it 
was interesting to compare the data from the modified method with that from another 
established measure of supra-gingival plaque accumulation, the TPI, and to assess 
repeatability of the method. Good agreement in treatment efficacy findings was obtained 
using both planimetric and TPI methods. Examiner repeatability for plaque area was 
excellent using the new planimetric method. Whilst the TPI method of recording plaque is 
simpler, planimetric data have been shown to provide an additional level of detail regarding 
plaque levels and distribution(32), which can add value in evaluating efficacy of agents, with 
the CPlaque app dramatically reducing the time taken to capture data by this method. 
 
 
Conclusions 
The aim of this exploratory study was to evaluate the effect of three 5.0% w/w CSPS 
dentifrices, a comparator mouthwash and a negative control dentifrice on plaque re-growth in 
a non-brushing model after 4 days of twice daily use. Overall, 4-day plaque re-growth was 
lowest for the active comparator (Listerine Cool Mint Antibacterial Mouthwash), which was 
significantly more effective in the inhibition of plaque re-growth than the dentifrice 
treatments investigated for the plaque measures employed. In this clinical study, SLS-
containing dentifrices were shown to be more effective in reducing plaque re-growth than a 
dentifrice with an alternative tegobetaine/adinol surfactant system. The tablet application 
used to record and calculate plaque area had the virtue of direct data entry, automatic 
calculation of percentage plaque area and the ability to re-visit the source data for 
verification; it provided similar efficacy data in the present study to the TPI, a well-
established tool for the assessment of supra-gingival plaque accumulation. 
  
19 
 
Conflict of Interest and funding statement 
Conflict of interest, source of funding and author contribution statement: CH and AH are 
employees of GSK Consumer Healthcare; DS is a contractor, funded by GSK Consumer 
Healthcare. The study was carried out by the Clinical Trials Unit at Bristol Dental Hospital. 
CH, AH and DS were not involved in any aspect of the clinical trial data collection. NCAC, 
JS, MD and NXW all report grants from GSK Consumer Healthcare during the conduct of 
the study.  
CH, AJD, DS, NXW, MD, JS and NCAC contributed to the design and reporting of the study. 
NXW, JS and NCAC were involved in the conduct of the study. All authors had access to the 
final study report, made contributions to the development of the manuscript, had final 
responsibility for the decision to submit, and approved the submitted version 
 
The study was sponsored and funded by GSK Consumer Healthcare, Weybridge, UK. 
 
Acknowledgements 
The authors wish to thank Alex Ferrier, GSK Consumer Healthcare, for overall study 
management  
3 
 
Table 1: Study treatments and mode of administration 
Treatment name Composition Administration  
Experimental 5% CSPS dentifrice 
 
5% CSPS/927 ppm fluoride as SMFP* 
with tegobetaine/adinol (RDA**~160)  
Dentifrices were administered as an 
aqueous slurry (1.5 g ± 0.1 g dentifrice, 
dispersed in 10 ml injection quality water 
using a bench top speed mixer). Slurries 
were administered within 5 minutes of 
preparation. 
Volunteers rinsed with slurry for 1 minute 
and were not permitted to rinse with water 
after expectorating. 
Marketed 5% CSPS dentifrice [1]  
(UK Sensodyne® Repair & Protect 
Whitening; GSK Consumer Healthcare, 
Weybridge, UK) 
5% CSPS/1450 ppm fluoride as SMFP* 
with SLS*** (RDA~140) 
Marketed 5% CSPS dentifrice [2] 
(UK Sensodyne® Repair & Protect; GSK 
Consumer Healthcare, Weybridge, UK) 
% CSPS/1450 ppm fluoride as SMFP with 
SLS (RDA~100)  
Negative control dentifrice  
(UK Crest® Decay Prevention; Procter & 
Gamble UK, Weybridge, UK) 
1450 ppm fluoride as NaF with SLS 
Active Comparator (Listerine® Cool Mint 
Antibacterial Mouthwash; Johnson & 
Johnson Ltd, Wokingham, UK) 
Eucalyptol, menthol, methyl salicylate and 
thymol  
Mouthwash (20 ml) was administered 
undiluted, according to the manufacturer’s 
instructions. Volunteers rinsed for 30 
seconds and were not permitted to rinse 
with water after expectorating. 
*SMFP = sodium monofluorophosphate; **RDA= relative dentine abrasivity; ***SLS = sodium lauryl sulphate; NaF = sodium fluoride 
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Table 2: TPI scoring system 
Score Definition 
0 No plaque 
1 Slight flecks of plaque at the cervical margin of the tooth 
2 Thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth 
3 Band of plaque wider than 1 mm but covering less that 1/3 of the area 
4 Plaque covering at least 1/3 but less than 2/3 of the area 
5 Plaque covering 2/3 or more of the crown of the tooth 
 
3 
 
Table 3 Analysis of mean plaque area (%) and TPI at 96 hours—ITT Population 
Treatment comparison 
 
Treatment difference 
(95% CI) p-value1 
0–96 hour plaque 
area 
(all surfaces) 
0–96 hour plaque area 
(facial/buccal 
surfaces) 
0–96 hour TPI          
(all surfaces) 
Experimental 5% CSPS dentifrice vs marketed 5% CSPS dentifrice [1]  4.85 (2.11, 7.59) 
p=0.0007 
5.84 (2.13, 9.55) 
p=0.0024 
0.18 (0.07, 0.28) 
p=0.0011 
Experimental 5% CSPS dentifrice vs marketed 5% CSPS
 
dentifrice [2] 7.66 (4.92, 10.41) 
p<0.0001 
8.96 (5.24, 12.68) 
p<0.0001 
0.27 (0.17, 0.38) 
p<0.0001 
Experimental 5% CSPS dentifrice vs active comparator  15.52 (12.78, 18.26) 
p<0.0001 
20.29 (16.58, 24.01) 
p<0.0001 
0.60 (0.50, 0.71) 
p<0.0001 
Experimental 5% CSPS dentifrice vs negative control 6.42 (3.62, 9.21) 
p<0.0001 
8.48 (4.69, 12.27) 
p<0.0001 
0.23 (0.12, 0.33) 
p<0.0001 
Marketed 5% CSPS dentifrice [1] vs marketed 5% CSPS dentifrice [2]  2.82 (0.15, 5.48) 
p=0.0386 
3.12 (–0.49, 6.73) 
p=0.0897 
0.10 (0.00, 0.20) 
p=0.0619 
Marketed 5% CSPS dentifrice [1] vs active comparator 10.67 (8.01, 13.34) 
p<0.0001 
14.45 (10.85, 18.06) 
p<0.0001 
0.43 (0.32, 0.53) 
p<0.0001 
Marketed 5% CSPS dentifrice [1] vs negative control 1.57 (–1.14, 4.28) 
p=0.2524 
2.64 (–1.03, 6.31) 
p=0.1564 
0.05 (–0.06, 0.15) 
p=0.3636 
Marketed 5% CSPS dentifrice [2] vs active comparator 7.85 (5.19, 10.52) 
p<0.0001 
11.34 (7.72, 14.95) 
p<0.0001 
0.33 (0.23, 0.43) 
p<0.0001 
Marketed 5% CSPS dentifrice [2] vs negative control –1.25 (–3.95, 1.45) 
p=0.3607 
–0.48 (–4.14, 3.18) 
p=0.7953 
–0.05 (–0.15, 
0.05) p=0.3439 
Active comparator vs negative control  –9.10 (–11.81, –
6.40) p<0.0001 
–11.81 (–15.48, –
8.15) p<0.0001 
–0.38 (–0.48, –
0.28) p<0.0001 
1Mean difference (95% CI) adjusted for other factors in the model 
Marketed 5% CSPS dentifrice [1] = Sensodyne Repair and Protect Whitening 
Marketed 5% CSPS dentifrice [2] = Sensodyne Repair and Protect 
Active comparator = Listerine Cool Mint antibacterial mouth wash 
Negative control = Crest Decay Prevention with SLS 
Note: A negative value favours the first mentioned treatment. 
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Fig. 1: Standard Tooth Chart for recording plaque area. 
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Fig. 2: Plaque re-growth scores 
(A) Plaque re-growth as measured as percentage plaque area, graph shows the mean percentage of 
plaque re-growth area ± SE as measured using the plaque application for all tooth surfaces and for 
facial/buccal surfaces 
 
(B) Plaque re-growth as measured by TPI, graph shows the mean TPI score ± SE 
 
Treatments are as follows:  
[1] Experimental 5% CSPS dentifrice (with tegobetaine/adinol; n=21)  
[2] Marketed 5% CSPS dentifrice [1] (with SLS; n=23),  
[3] Marketed 5% CSPS dentifrice [2] (with SLS; n=23), 
[4] Active comparator (n=23),  
[5] Negative control (n=22) 
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